Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HRQoL deteriorates during chemoradiotherapy for bladder cancer

Key clinical point: An exploratory analysis suggests chemoradiotherapy impairs health-related quality of life (HRQoL) during and immediately following treatment in patients with muscle-invasive bladder cancer.

Major finding: HRQoL scores deteriorated at end of treatment (bladder cancer subscale: –5.06; 99% CI, –6.12 to –4.00), but improved to pretreatment levels at 6 months, and were maintained thereafter.

Study details: A subset analysis of HRQoL data for 452 patients from the phase 3 BC2001 trial.

Disclosures: Cancer Research UK funded the study. The authors reported having no conflicts of interest.

Citation:

Huddart RA et al. Eur Urol. 2019 Dec 13. doi: 10.1016/j.eururo.2019.11.001.